Cargando…

De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?

SIMPLE SUMMARY: De novo metastatic hormone-sensitive prostate cancer usually has a dismal prognosis, which has slightly improved in recent years thanks to the introduction of new hormonal agents and chemotherapy combined with androgen deprivation therapy from the first-line setting. The randomized c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piombino, Claudia, Oltrecolli, Marco, Tonni, Elena, Pirola, Marta, Matranga, Rossana, Baldessari, Cinza, Pipitone, Stefania, Dominici, Massimo, Sabbatini, Roberto, Vitale, Maria Giuseppa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605467/ https://www.ncbi.nlm.nih.gov/pubmed/37894312 http://dx.doi.org/10.3390/cancers15204945

Ejemplares similares

Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications
por: Baldessari, Cinzia, et al.
Publicado: (2023)

Chasing the Role of miRNAs in RCC: From Free-Circulating to Extracellular-Vesicle-Derived Biomarkers
por: Mastrolia, Ilenia, et al.
Publicado: (2023)

Editorial: The ever-changing scenario of first line treatment of metastatic renal cell carcinoma
por: Vitale, Maria Giuseppa, et al.
Publicado: (2023)

Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report
por: Cortesi, Laura, et al.
Publicado: (2022)

Personalized Systemic Therapies in Hereditary Cancer Syndromes
por: Mastrodomenico, Luciana, et al.
Publicado: (2023)

The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting
por: Salati, Massimiliano, et al.
Publicado: (2021)

Moving towards Personalized Medicine in Muscle-Invasive Bladder Cancer: Where Are We Now and Where Are We Going?
por: Pardo, Juan Carlos, et al.
Publicado: (2020)

We Move in Mysterious Ways
Publicado: (2004)

We Move or Are We Moved? Unpicking the Origins of Voluntary Movements to Better Understand Semivoluntary Movements
por: Virameteekul, Sasivimol, et al.
Publicado: (2022)

Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
por: Omarini, Claudia, et al.
Publicado: (2018)

IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting
por: Salati, Massimiliano, et al.
Publicado: (2020)

Burkholderia vaccines: are we moving forward?
por: Choh, Leang-Chung, et al.
Publicado: (2013)

Vulnerability to Disasters: Are We Moving Ahead?
por: Shrivastava, Saurabh R, et al.
Publicado: (2012)

The Role of Exosomes in Breast Cancer Diagnosis
por: Piombino, Claudia, et al.
Publicado: (2021)

Can we resist another person’s gaze?
por: Marino, Barbara F. M., et al.
Publicado: (2015)

“If we move, it moves with us:” Physical distancing in Africa during COVID-19
por: Bicalho, Clara, et al.
Publicado: (2021)

Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis
por: Salati, Massimiliano, et al.
Publicado: (2018)

Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma
por: Salati, Massimiliano, et al.
Publicado: (2022)

Innovative Therapeutic Strategies for Cystic Fibrosis: Moving Forward to CRISPR Technique
por: Marangi, Michele, et al.
Publicado: (2018)

Metastatic cells: moving onco-targets
por: Patsialou, Antonia, et al.
Publicado: (2014)

Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?
por: Audisio, Marco, et al.
Publicado: (2022)

We’re moving forward…join the momentum!
por: Nichani, Ashish Sham
Publicado: (2015)

Move: Durational Dance-Making as We Age
por: Nikolai, Jennifer
Publicado: (2022)

Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)
por: Maruzzo, Marco, et al.
Publicado: (2021)

Moving to Personalized Medicine Requires Personalized Health Plans
por: Powell, Adam, et al.
Publicado: (2022)

Metabolomics: moving towards personalized medicine
por: Baraldi, Eugenio, et al.
Publicado: (2009)

Biological effects of COVID-19 on lung cancer: Can we drive our decisions
por: Aramini, Beatrice, et al.
Publicado: (2022)

Music to move persons with Parkinson’s disease: a personalized approach
por: Holter, Susanne Ten, et al.
Publicado: (2021)

Colorectal Cancer Screening: Where We Are and Moving Forward
por: Lightdale, Charles J.
Publicado: (2020)

New Mobilities and Psychology: Why are We Still Not on the Move?
por: Glăveanu, Vlad P.
Publicado: (2020)

Healthcare for Older Adults, Where Are We Moving towards?
por: Tarazona-Santabalbina, Francisco José, et al.
Publicado: (2021)

How we treat metastatic colorectal cancer
por: De Falco, Vincenzo, et al.
Publicado: (2020)

Redistribution of CD8+ T cell subsets in metastatic renal cell carcinoma patients treated with anti‐PD‐1 therapy
por: De Biasi, Sara, et al.
Publicado: (2022)

Moving towards personalized medicine in rheumatoid arthritis
por: de Jong, Tamarah D, et al.
Publicado: (2014)

Myelodysplastic syndromes: moving towards personalized management
por: Hellström-Lindberg, Eva, et al.
Publicado: (2020)

A Moving Source of Matrix Components Is Essential for De Novo Basement Membrane Formation
por: Matsubayashi, Yutaka, et al.
Publicado: (2017)

“We Were Just Taking Our Marching Orders and Moving Forward With Whatever We Were Given”: Policy Implications of Pandemic Quarantine and Social Isolation in Older Persons
por: Koszalinski, Rebecca S, et al.
Publicado: (2022)

Why Do We have to Move Fluid to be Able to Breathe?
por: Fronius, Martin, et al.
Publicado: (2012)

Tracheostomy practice in a uk dgh: are we moving with the times?
por: Donaldson, F, et al.
Publicado: (2015)

Are we moving towards a new definition of essential medicines?
por: Manikandan, S
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_94dqjk8gbfs7crhg8cvkmia2lf